ATHENA: Identifying interactions between different levels of genomic data associated with cancer clinical outcomes using grammatical evolution neural network

BioData Mining

Volumn 6, Issue 1, 2013, Pages

  Kim, Dokyoon ^a   Li, Ruowang ^a   Dudek, Scott M ^a   Ritchie, Marylyn D ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Grammatical evolution neural network; Integrative analysis; Multi omics data; Ovarian cancer

Indexed keywords

EID: 84890485602     PISSN: None     EISSN: 17560381     Source Type: Journal    
DOI: 10.1186/1756-0381-6-23     Document Type: Article

References (50)

1. Oncogenes and cancer. Croce CM, N Engl J Med 2008 358 5 502 511 10.1056/NEJMra072367 18234754 (Pubitemid 351185806)
2. Prediction of central nervous system embryonal tumour outcome based on gene expression. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, et al. Nature 2002 415 6870 436 442 10.1038/415436a 11807556 (Pubitemid 34100955)
3. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, et al. Cancer Cell 2002 1 2 133 143 10.1016/S1535-6108(02)00032-6 12086872 (Pubitemid 41039160)
4. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, et al. Nat Med 2002 8 1 68 74 10.1038/nm0102-68 11786909 (Pubitemid 34101731)
5. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. Nat Med 2002 8 8 816 824 12118244
6. Gene expression profiling predicts clinical outcome of breast cancer. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Nature 2002 415 6871 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
7. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Ntzani EE, Ioannidis JP, Lancet 2003 362 9394 1439 1444 10.1016/S0140-6736(03)14686-7 14602436 (Pubitemid 37352879)
8. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Michiels S, Koscielny S, Hill C, Lancet 2005 365 9458 488 492 10.1016/S0140-6736(05)17866-0 15705458 (Pubitemid 40215731)
9. The concept of synthetic lethality in the context of anticancer therapy. Kaelin WG Jr, Nat Rev Cancer 2005 5 9 689 698 10.1038/nrc1691 16110319 (Pubitemid 41486362)
10. Integrated global profiling of cancer. Hanash S, Nat Rev Cancer 2004 4 8 638 644 10.1038/nrc1414 15286743 (Pubitemid 39025058)
11. Comprehensive molecular characterization of human colon and rectal cancer. TCGA Network, Nature 2012 487 7407 330 337 10.1038/nature11252 22810696
12. Comprehensive genomic characterization of squamous cell lung cancers. TCGA Network, Nature 2012 489 7417 519 525 10.1038/nature11404 22960745
13. Comprehensive molecular portraits of human breast tumours. TCGA Network, Nature 2012 490 7418 61 70 10.1038/nature11412 23000897
14. Integrated genomic analyses of ovarian carcinoma. TCGA Network, Nature 2011 474 7353 609 615 10.1038/nature10166 21720365
15. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. TCGA Network, Nature 2008 455 7216 1061 1068 10.1038/nature07385 18772890
16. International network of cancer genome projects. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, International Cancer Genome Consortium, et al. Nature 2010 464 7291 993 998 10.1038/nature08987 20393554
17. Synergistic effect of different levels of genomic data for cancer clinical outcome prediction. Kim D, Shin H, Song YS, Kim JH, J Biomed Inform 2012 45 6 1191 1198 10.1016/j.jbi.2012.07.008 22910106
18. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. Cancer Cell 2010 17 5 510 522 10.1016/j.ccr.2010.03.017 20399149
19. A ten-microRNA expression signature predicts survival in glioblastoma. Srinivasan S, Patric IR, Somasundaram K, PLoS One 2011 6 3 17438 10.1371/journal.pone.0017438 21483847
20. Protein-protein interactions for cancer therapy. Harris CC, Proc Natl Acad Sci USA 2006 103 6 1659 1660 10.1073/pnas.0510948103 16452164 (Pubitemid 43228750)
21. MicroRNA Response Elements-Mediated miRNA-miRNA Interactions in Prostate Cancer. Alshalalfa M, Adv Bioinformatics 2012 2012 839837 23193399
22. MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features. Xu J, Li CX, Li YS, Lv JY, Ma Y, Shao TT, Xu LD, Wang YY, Du L, Zhang YP, et al. Nucleic Acids Res 2011 39 3 825 836 10.1093/nar/gkq832 20929877
23. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et al. Science 2012 335 6066 348 353 10.1126/science.1212728 22157079
24. Impact of microRNA regulation on variation in human gene expression. Lu J, Clark AG, Genome Res 2012 22 7 1243 1254 10.1101/gr.132514.111 22456605
25. Copy number variation influences gene expression and metabolic traits in mice. Orozco LD, Cokus SJ, Ghazalpour A, Ingram-Drake L, Wang S, van Nas A, Che N, Araujo JA, Pellegrini M, Lusis AJ, Hum Mol Genet 2009 18 21 4118 4129 10.1093/hmg/ddp360 19648292
26. Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. Dudziec E, Gogol-Doring A, Cookson V, Chen W, Catto J, PLoS One 2012 7 3 32750 10.1371/journal.pone.0032750 22412920
27. Cancer statistics, 2009. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, CA Cancer J Clin 2009 59 4 225 249 10.3322/caac.20006 19474385
28. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. Cancer Discov 2012 2 5 401 404 10.1158/2159-8290.CD-12-0095 22588877
29. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. Nature 2006 439 7074 353 357 10.1038/nature04296 16273092 (Pubitemid 43128862)
30. ATHENA: the analysis tool for heritable and environmental network associations. Holzinger ER, Dudek SM, Frase AT, Pendergrass SA, Ritchie MD, Bioinformatics 2013 epub
31. ATHENA: A knowledge-based hybrid backpropagation-grammatical evolution neural network algorithm for discovering epistasis among quantitative trait Loci. Turner SD, Dudek SM, Ritchie MD, BioData Mining 2010 3 1 5 10.1186/1756-0381-3-5 20875103
32. ATHENA: a tool for meta-dimensional analysis applied to genotypes and gene expression data to predict HDL cholesterol levels. Holzinger ER, Dudek SM, Frase AT, Krauss RM, Medina MW, Ritchie MD, Pac Symp Biocomput 2013 385 396
33. Detecting gene-gene interactions that underlie human diseases. Cordell HJ, Nat Rev Genet 2009 10 6 392 404 10.1038/nrg2579 19434077
34. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH, Am J Hum Genet 2001 69 1 138 147 10.1086/321276 11404819 (Pubitemid 32614026)
35. Optimization of neural network architecture using genetic programming improves detection and modeling of gene-gene interactions in studies of human diseases. Ritchie MD, White BC, Parker JS, Hahn LW, Moore JH, BMC Bioinforma 2003 4 28 10.1186/1471-2105-4-28 (Pubitemid 38751242)
36. Comparison of approaches for machine-learning optimization of neural networks for detecting gene-gene interactions in genetic epidemiology. Motsinger-Reif AA, Dudek SM, Hahn LW, Ritchie MD, Genet Epidemiol 2008 32 4 325 340 10.1002/gepi.20307 18265411 (Pubitemid 351656304)
37. Genetic programming neural networks: a powerful bioinformatics tool for human genetics. Ritchie MD, Motsinger AA, Bush WS, Coffey CS, Moore JH, Appl Soft Comput 2007 7 1 471 479 10.1016/j.asoc.2006.01.013 20948988 (Pubitemid 44739447)
38. Comparison of methods for meta-dimensional data analysis using in silico and biological data sets. Holzinger ER, Dudek SC, Frase AT, Fridley BL, Chalise P, Ritchie MD, Lect Notes Comput Sci 2012 7246 134 143 10.1007/978-3-642-29066- 4-12
39. Statistical comparisons of classifiers over multiple data sets. Demsar J, J Mach Learn Res 2006 7 1 30 (Pubitemid 43022939)
40. MicroRNA in cancer: the involvement of Aberrant MicroRNA Biogenesis regulatory pathways. Davis-Dusenbery BN, Hata A, Genes Cancer 2010 1 11 1100 1114 10.1177/1947601910396213 21533017
41. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, et al. Cancer Res 2011 71 11 3841 3851 10.1158/0008-5472.CAN-10-4391 21498633
42. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al. Cancer Cell 2006 9 3 189 198 10.1016/j.ccr.2006.01.025 16530703 (Pubitemid 43357945)
43. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, et al. PLoS One 2010 5 9 doi: 10.1371/journal.pone.0011408
44. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C, Cancer Res 1997 57 19 4360 4367 9331099 (Pubitemid 27413447)
45. Epigenetic epistatic interactions constrain the evolution of gene expression. Park S, Lehner B, Mol Syst Biol 2013 9 645 23423319
46. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I, Iversen ES, Berchuck A, Murphy SK, Genome Res 2011 21 1 74 82 10.1101/gr.108803.110 21156726
47. Relaxin-like peptides in cancer. Silvertown JD, Summerlee AJ, Klonisch T, Int J Cancer 2003 107 4 513 519 10.1002/ijc.11424 14520686 (Pubitemid 37296109)
48. Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness. Klonisch T, Bialek J, Radestock Y, Hoang-Vu C, Hombach-Klonisch S, Adv Exp Med Biol 2007 612 104 118 10.1007/978-0-387-74672-2-8 18161484
49. miRBase: tools for microRNA genomics. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ, Nucleic Acids Res 2008 36 Database issue 154 D158 17991681
50. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, Kleijer WJ, DiMaio D, Hwang ES, Aging Cell 2006 5 2 187 195 10.1111/j.1474-9726.2006.00199.x 16626397 (Pubitemid 44056509)